Seeking Alpha

Immunogen gives back early gains from an upbeat FQ4 report

  • ImmunoGen (IMGN -1.2%) gives back yesterday's post-session gains and more after its FQ4 beat on a per share basis, reporting a narrower loss than the Street.
  • Kadcyla sales off to a strong start in the U.S. for its first indication, with additional approvals expected.
  • The company boosts guidance going forward, now expecting FY14 revenues of $66M - $70M, above the Street view of $49.9M.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector